Literature DB >> 17008108

Neuronal neprilysin overexpression is associated with attenuation of Abeta-related spatial memory deficit.

Raphael Poirier1, David P Wolfer, Hans Welzl, Jay Tracy, Michael J Galsworthy, Roger M Nitsch, M Hasan Mohajeri.   

Abstract

Converging evidence links abnormally high brain concentrations of amyloid-beta peptides (Abeta) to the pathology of Alzheimer's disease (AD). Lowering brain Abeta levels, therefore, is a therapeutic strategy for the treatment of AD. Neuronal neprilysin upregulation led to increased degradation of Abeta, reduced the formation of Abeta-plaques and the associated cytopathology, but whether overexpression of neprilysin can improve cognition is unknown. We show that neuronal overexpression of neprilysin improved the Morris water maze memory performance in mice with memory deficits resulting from overexpression of the AD-causing mutated human amyloid precursor protein (APP). This improvement was associated with decreased brain levels of Abeta and with unchanged endoproteolytic processing of APP. These results provide the evidence that lowering of brain Abeta levels by increasing its degradation can improve cognitive functions in vivo, and suggest that increasing the activity of neprilysin in brain may be effective in preventing cognitive decline in AD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17008108     DOI: 10.1016/j.nbd.2006.08.003

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  27 in total

Review 1.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

2.  Wet or dry: translatable "water mazes" for mice and humans.

Authors:  Kerin K Higa; Jared W Young; Mark A Geyer
Journal:  J Clin Invest       Date:  2016-01-19       Impact factor: 14.808

3.  Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease.

Authors:  Salim S El-Amouri; Hong Zhu; Jin Yu; Robert Marr; Inder M Verma; Mark S Kindy
Journal:  Am J Pathol       Date:  2008-04-10       Impact factor: 4.307

Review 4.  Innate immune activation in Alzheimer's disease.

Authors:  Ming-Ming Wang; Dan Miao; Xi-Peng Cao; Lin Tan; Lan Tan
Journal:  Ann Transl Med       Date:  2018-05

5.  Proteomic analysis of the amyloid precursor protein fragment C99: expression in yeast.

Authors:  Louis J Sparvero; Sarah Patz; Jeffrey L Brodsky; Christina M Coughlan
Journal:  Anal Biochem       Date:  2007-08-10       Impact factor: 3.365

6.  Neprilysin-2 is an important β-amyloid degrading enzyme.

Authors:  Daniel Hafez; Jeffrey Y Huang; Alexis M Huynh; Stephanie Valtierra; Edward Rockenstein; Angela M Bruno; Bao Lu; Luc DesGroseillers; Eliezer Masliah; Robert A Marr
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

Review 7.  Type 2 diabetes as a protein misfolding disease.

Authors:  Abhisek Mukherjee; Diego Morales-Scheihing; Peter C Butler; Claudio Soto
Journal:  Trends Mol Med       Date:  2015-05-18       Impact factor: 11.951

8.  Olive-oil-derived oleocanthal enhances β-amyloid clearance as a potential neuroprotective mechanism against Alzheimer's disease: in vitro and in vivo studies.

Authors:  Alaa H Abuznait; Hisham Qosa; Belnaser A Busnena; Khalid A El Sayed; Amal Kaddoumi
Journal:  ACS Chem Neurosci       Date:  2013-02-25       Impact factor: 4.418

Review 9.  Transgenic Drosophila models of Alzheimer's disease and tauopathies.

Authors:  Kanae Iijima-Ando; Koichi Iijima
Journal:  Brain Struct Funct       Date:  2009-12-05       Impact factor: 3.270

10.  Drosophila Neprilysins Are Involved in Middle-Term and Long-Term Memory.

Authors:  Oriane Turrel; Aurélie Lampin-Saint-Amaux; Thomas Préat; Valérie Goguel
Journal:  J Neurosci       Date:  2016-09-14       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.